18630437. ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS simplified abstract (Merck Sharp & Dohme LLC)

ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS

Organization Name

Merck Sharp & Dohme LLC

Inventor(s)

Kalpit A. Vora of Yardley PA (US)

Kara S. Cox of Harleysville PA (US)

Aimin Tang of Lansdale PA (US)

Zhifeng Chen of Warrington PA (US)

Daniel Distefano of Harleysville PA (US)

Lan Zhang of Chalfont PA (US)

Hua-Poo Su of Phoenixville PA (US)

ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS - A simplified explanation of the abstract

This abstract first appeared for US patent application 18630437 titled 'ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS

The present invention involves monoclonal antibodies with high anti-RSV neutralizing titers, along with isolated nucleic acids encoding these antibodies and host cells transformed with them. The invention also includes diagnostic, prophylactic, and therapeutic methods using the antibodies and nucleic acids, especially for passive immunotherapy in infants and the elderly.

• Monoclonal antibodies with high anti-RSV neutralizing titers
• Isolated nucleic acids encoding the antibodies
• Host cells transformed with the nucleic acids
• Diagnostic, prophylactic, and therapeutic methods using the antibodies and nucleic acids
• Passive immunotherapy in infants and the elderly

Potential Applications: - Treatment of RSV infections - Prevention of RSV infections in high-risk populations - Development of new immunotherapy agents

Problems Solved: - Lack of effective treatments for RSV infections - Limited options for passive immunotherapy in infants and the elderly

Benefits: - Improved outcomes for RSV patients - Enhanced protection against RSV in vulnerable populations - Potential for new therapeutic interventions

Commercial Applications: Title: "High Anti-RSV Monoclonal Antibodies: Commercial Potential and Market Impact" Description: The technology can be utilized in the development of novel RSV treatments, catering to a significant market demand for effective solutions against this respiratory virus.

Questions about the technology: 1. How do these monoclonal antibodies compare to existing treatments for RSV infections? 2. What are the potential challenges in scaling up production of these antibodies for widespread use?

Original Abstract Submitted

The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.